MARKET

TYME

TYME

Tyme Technologies Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2890
+0.0252
+9.55%
Opening 09:43 06/29 EDT
OPEN
0.2600
PREV CLOSE
0.2638
HIGH
0.2900
LOW
0.2600
VOLUME
213.51K
TURNOVER
43.38K
52 WEEK HIGH
2.020
52 WEEK LOW
0.2187
MARKET CAP
49.77M
P/E (TTM)
-2.1064
1D
5D
1M
3M
1Y
5Y
BRIEF-Tyme Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard
BRIEF-Tyme Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard
Reuters · 6d ago
Tyme Technologies Non-GAAP EPS of -$0.13
Tyme Technologies press release (NASDAQ:TYME): FY Non-GAAP EPS of -$0.13. As of March 31, 2022, the Company had approximately $84.0 million in cash and marketable securities, compared to $92.0 million
Seekingalpha · 05/25 11:55
-- Earnings Flash (TYME) TYME TECHNOLOGIES Posts 2022 Loss of $-0.14
MT Newswires · 05/25 08:01
Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Simply Wall St. · 05/23 12:28
TYME Technologies Reviews Potential Strategic Options
Benzinga · 03/29 15:38
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 03/29 11:41
BRIEF-Tyme Technologies Inc Announces Exploration Of Strategic Options
reuters.com · 03/29 11:09
Tyme Technologies shares jump premarket on news board to explore strategic options
Tyme Technologies Inc. , a biotech developing cancer metabolism-based treatments, said Tuesday its board has decided to explore its strategic options and has hired Moelis & Co. as a financial adviser and Faegre Drinker Biddle & Reath LLP as its legal advis...
marketwatch.com · 03/29 11:01
More
No Data
Learn about the latest financial forecast of TYME. Analyze the recent business situations of Tyme Technologies Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TYME stock price target is 9.50 with a high estimate of 9.50 and a low estimate of 9.50.
High9.50
Average9.50
Low9.50
Current 0.2845
EPS
Actual
Estimate
-0.05-0.04-0.02-0.01
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 86
Institutional Holdings: 16.80M
% Owned: 9.76%
Shares Outstanding: 172.21M
TypeInstitutionsShares
Increased
8
1.49M
New
8
373.24K
Decreased
16
2.47M
Sold Out
13
385.49K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.18%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Director
Douglas Michels
Chief Executive Officer/Director
Richard Cunningham
Chief Financial Officer
Frank Porfido
Executive Vice President
John Rothman
Other
Jonathan Eckard
Other
Jan Van Tornout
Secretary
James Biehl
Director
Christine Baker
Independent Director
David Carberry
Independent Director
Donald Degolyer
Independent Director
Gerald Sokol
Independent Director
Paul Sturman
Independent Director
Timothy Tyson
No Data
No Data
About TYME
Tyme Technologies, Inc. is a biotechnology company. The Company is focused on developing cancer metabolism-based therapies (CMBTs) for a range of solid tumors and hematologic cancers. The Company's lead clinical CMBT compound, SM-88, is an oral investigational modified tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cell's key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. It is also developing SM-88i, an injectable formulation of SM-88 for the treatment of multiple oncology indications. Its TYME-18, is a pre-clinical CMBT designed for the intra-tumoral delivery of the treatment and increase the permeability of cancer cells, while delivering a therapy having selective cytotoxic effect on the tumor. Its TYME-19, is an oral, synthetically produced member of the bile acid family that is being developed for the potential treatment of COVID-19.

Webull offers kinds of Tyme Technologies Inc stock information, including NASDAQ:TYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYME stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TYME stock methods without spending real money on the virtual paper trading platform.